Prevaccination distribution of human papillomavirus types in women attending at cervical cancer screening in Belgium

Cancer Epidemiology Biomarkers and Prevention

Volumn 18, Issue 1, 2009, Pages 321-330

  Arbyn, Marc ^a   Benoy, Ina ^b   Simoens, Cindy ^a   Bogers, Johannes ^b   Beutels, Philippe ^b   Depuydt, Christophe ^b  

^a SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN E6; PROTEIN E7; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BELGIUM; CANCER SCREENING; CONTROLLED STUDY; CYTOLOGY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 52; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS; WART VIRUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BELGIUM; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UTERINE CERVICAL NEOPLASMS;

EID: 58349090025     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0510     Document Type: Article

References (58)

1. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F. Carcinogenicity of human papillomaviruses. Lancet Oncol 2005;6:204.
2. zur Hausen H, Arbyn M, Villa L, et al.; IARC Monograph Working Group. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 90. Human papillomaviruses. Lyon: IARC Press; 2007.
3. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. Vaccine 2006;24 S3:78-89.
4. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
5. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J. Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280-93.
6. Koutsky LA, Harper DM. Chapter 13: Current findings from prophylactic HPV vaccine trials. Vaccine 2006;24:114-21.
7. Stanley M, Lowy DR, Frazer I. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006;24:106-13.
8. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ : a combined analysis of four randomised clinical trials. Lancet 2007;369:1861-8.
9. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369:1693-702.
10. Franceschi S, Herrero R, Clifford GM, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119:2677-84.
11. Clifford GM, Gallus S, Herrero R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366:991-8.
12. Depuydt C, Vereecken AJ, Salembier GM, et al. Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer 2003;88:560-6.
13. Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007;18:133-9.
14. Vassilakos P, Saurel J, Rondez R. Direct-to-vial use of the Aut PREP liquid-based preparation for cervical-vaginal specimens in three European laboratories. Acta Cytol 1999;43:65-8.
15. Vassilakos P, Griffin S, Megevand E, Campana A. CytoRich liquid-based cervical cytologic test. Screening results in a routine cytopathology service. Acta Cytol 1998;42:198-202.
16. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9.
17. Herbert A, Bergeron C, Wiener H, Schenck U, Klinkhamer PJ, Arbyn M. European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology. Cytopathology 2007;18:213-9.
18. Depuydt C, Benoy IH, Bailleul EJ, Vandepitte J, Vereecken AJ, Bogers JJ. Improved endocervical sampling and HPV viral load detection by Cervex-Brush Combi. Cytopathology 2006;17:374-81.
19. Depuydt CE, Boulet GA, Horvath CA, Benoy IH, Vereecken AJ, Bogers JJ. Comparison of MY09/11 consensus PCR and type-specific PCRs in the detection of oncogenic HPV types. J Cell Mol Med 2007;11:881-91.
20. Weyers S, Crijns P, De Sutter P, et al. Opvolging na afwijkende cervixcytologie. Tijdschr voor Geneeskunde 2005;61:129-34.
21. Arbyn M, Van Oyen H. Cervical cancer screening in Belgium. Eur J Cancer 2000;36:2191-7.
22. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
23. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006;24:1-10.
24. Merenne B, Van Der Haegen H, Van Hecke E. La Belgique: diversité territoriale. Bulletin du Crédit Communal 1997;202:1-144.
25. Sasieni P, Stepniewska K, Altman D. Test for trend across ordered groups revisited. Stata Tech Bull 1996;6:193-6.
26. Hosmer DW, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons; 1989.
27. Arbyn M, Bourgain C, De Sutter P, et al. Triage HPV detection versus primary HPV screening in combination with liquid-based cytology: a randomised trial. Brussels: Scientific Institute of Public Health; 2001. Report No.: 6.
28. Baay MF, Tjalma WA, Weyler J, et al. Human papillomavirus infection in the female population of Antwerp, Belgium: prevalence in healthy women, women with premalignant lesions and cervical cancer. Eur J Gynaecol Oncol 2001;22:204-8.
29. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol Oncol 2006;103:12-7.
30. Arbyn M, Dillner J, Schenck U, et al. Chapter 3: Methods for screening and diagnosis. In: Arbyn M, Anttila A, Jordan J, et al., editors. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008. p. 69-152.
31. Depuydt CE, Arbyn M, Benoy IH, Vandepitte J, Vereecken A, Bogers JJ. Quality control for normal liquid-based cytology: rescreening, high risk HPV targeted reviewing and/or high risk HPV detection? J Cell Mol Med. 2008 Jun 9 (Epub ahead of print).
32. Arbyn M, Depuydt C. Distribution of HPV types in a population of 10 thousand Belgian women, screened for cervical cancer. Brussels: Scientific Institute of Public Health, RIATOL; 2007. Report No.: 20.
33. Beerens E, Van Renterghem L, Praet M, et al. Human papillomavirus DNA detection in women with primary abnormal cytology of the cervix: prevalence and distribution of HPV genotypes. Cytopathology 2005;16:199-205.
34. Clifford GM, Rana RK, Franceschi S, Smith JS, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157-64.
35. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
36. Sherman ME, Schiffman MA, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomised atypical squamous cells of undetermined significance/low-grade intraepithelial lesion triage study (ALTS). J Natl Cancer Inst 2002;94:102-7.
37. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN. An update of pooled evidence. Gynecol Oncol 2005;99:7-11.
38. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007;7:453-9.
39. Naucler P, Ryd W, Tornberg S, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007;97:129-32.
40. Sargent A, Bailey A, Almonte M, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008;98(10):1704-9.
41. Arbyn M. Effects of quadrivalent human papillomavirus vaccination. Lancet 2007;370:1031-2.
42. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4-5 years of bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
43. Villa LL, Costa RLR, Andrade RP, et al. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine through up to 5 years of follow-up. European Research Organization on Genital Infection and Neoplasia; 2006 Apr 26; Paris. 2006. p. 1.
44. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
45. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
46. FUTURE II Study Group. Supplementary appendix. N Engl J Med 2007;356:1915-27.
47. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743-53.
48. Ferris D. Efficacy of a quadrivalent HPV (types 6/11/16/18) L1 virus-like particle (VLP) vaccine in women with virologic evidence of HPV infection: a combined analysis [Abstract S11-2]. European Research Organization on Genital Infection and Neoplasia; 2006 Apr 26; Paris. 2006.
49. Luna J. The safety, efficacy and immunogenicity of quadrivalent HPV (types 6/11/16/18) L1 virus-like-particle (VLP) vaccine in women aged 24 to 45; oral presentation of abstract, plenary session (PA1-04). 24th International Papillomavirus Conference and Clinical Workshop; 2007 November 3-10; Beijing 2007.
50. Harper DM, Paavonen J. Age for HPV vaccination. Vaccine 2008;26:A7-11.
51. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70.
52. Gravitt PE, van Doorn LJ, Quint W, et al. Human papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin-embedded tissues to highlight difficulties in attributing HPV types to specific lesions. J Clin Microbiol 2007;45:3245-50.
53. Arbyn M, Andersson K, Bergeron C, Bogers JP, von Knebel-Doeberitz M, Dillner J. Chapter 16: cervical cytology biobanks as a resource for molecular epidemiology. Methods in biobanking. Tutowa (NJ): The Humana Press, Inc.; 2008.
54. Boulet GA, Horvath CA, Berghmans S, et al. Cervical cytology biobanking: quality of DNA from archival cervical Pap-smears. J Clin Pathol 2008;61:637-41.
55. Horvath CA, Boulet G, Sahebali S, et al. Effects of fixation on RNA integrity in a liquid-based cytology setting. J Clin Pathol 2007;10:1-13.
56. Dillner J, Arbyn M, Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol 2007;148:199-207.
57. Arbyn M, Dillner J. Review of current knowledge on HPV vaccination: an appendix to the European guidelines for quality assurance in cervical cancer screening. J Clin Virol 2007;38:189-97.
58. European Commission. European guidelines for quality assurance in cervical cancer screening. 2nd ed. Luxembourg: Office for Official Publications of the European Communities; 2008.